Grade My Investments
HomeFree Stock Grades › IMMX

Immix Biopharma, Inc. (IMMX) Stock Grade

IMMX · Healthcare

B
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$172.4M
P/E Ratio
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
Dividend Yield
None

About Immix Biopharma, Inc.'s fundamentals

Immix Biopharma is a biotechnology company with a market capitalization of $172.4 million that reported zero revenue growth year-over-year and operates at a net margin of 0.0% while carrying a net loss in its latest annual statement. The company pays no dividend and does not have calculable profitability metrics, reflecting its pre-revenue or early-stage development status typical of many biotechnology firms focused on pipeline advancement rather than current earnings.

Track IMMX free — no credit card required. Live grade + monthly AI report →